<DOC>
	<DOC>NCT01581853</DOC>
	<brief_summary>Lopinavir/ritonavir monotherapy is currently a well known and widely used strategy, while Lopinavir/ritonavir 800/200 mg once a day in a triple-therapy was approved a few years ago. The purpose of this study is to evaluate efficacy and safety of Lopinavir/ritonavir 800/200 mg monotherapy once a day.</brief_summary>
	<brief_title>Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Patients older than 18, HIV positive Patients receiving a monotherapy regimen (Lopinavir/ritonavir twice daily)during the last 6 months Undetectable viral load (&lt;40 copies/ml) during the last 6 months Patients that accept participation in the study and sign the Informed Consent Form Childbearing females with negative pregnancy tests and using appropriate contraceptive measures Opportunistic disease, cancer or any other active disease with specific treatment Active addiction to illegal drugs or active use of psychotropic drugs Mental retardation diagnosis, or mental dementia or severe psychiatric disorder (excluding major depression disorder solved &gt; 3 months) Females who are breastfeeding or pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>MONOTHERAPY</keyword>
	<keyword>PILOT</keyword>
	<keyword>LOPINAVIR/RITONAVIR</keyword>
</DOC>